Charlty rng18trallon nUmtr 1141310 CURE CANCER UCL CANCER INSTITUTE TRUSTEES. REPORT AND UNAUDITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2025
CURE CANCER @ UCL CANCER INSTITUTE LEGAL AND ADMINISTrATIVE INFORMATION S 8agho S Hamllton N Hamllton J Maryolln MBE S Sampwn FCA ¢haTRy number 1141310 Prlnclp•l addra•• Pltt Ho 120 Baker Streat London W1U 6TU Ind•pond•nt •xamln•r Unit 101. Flr8t Floor CeTrMntes House &9 He8dstone Road HA11PD Bankw8 Nat81 Bank PIC 9 The Broath Stsnmore Mlddle8ex HA7 4DA
CURE CANCER @ UCL CANCER INSTMJTE cop¥rENTS 7-11
CURE CANCER @ UCL CANCER INSTITUTE TRUSTEE8' REPORT FOR THE YEAR ENDED 31 AIARCH 2025 finandal sl8tement8 and Ihg Charit8 tgo¥effdng d0Ml, ts Ctrorftles Act 2011 and "Accwnllng and Reporlng ty Charltleg: Slotemert of Recommffidad Prndi¢ l¢able to Charl preparlng theEr acco In ac£4)rdance wllh the Finandd Rtyrydng S#ld in Ihe UK and Rep1 of Irdarrfl IFRS 102)" (affecll¥o 1 January 2019). ObJ•dlw and a¢tlvltles Cure Cancer UCL e¥ts to fuTrY rnsearth into PTrHry]gkn's Lymp1. The tharity foundad by Mrs Sandra Hamkn and 18 swwrted by Its Patron8: Prof8s8or knthony Goldstone. CBE (University Cdtego HospStal, Lond¢MI; Mrkndrns Ittrchls (Head ofts Cancer Unl( 88Tht Germl Fwld): Ractsl St•M. togother with a large and enthuslastic repres4 a ldo ofages and ex1nCe. Durfng the IhwKI81 >ar. Ilwough a (rf fvndrlry and donath. the ch8rty ralwj a trjlal of £39.723. Induded. butwag not Its)th to.. Fundralalng e¥•Nts . Amual Clarwnt E¥Irj IKted at ts V Hotsl, Elstre
CURE CANCER UCL CANCER INSTITUTE TRU8TEE8' REPORT (COPrnNUED) FOR THE YEAR ENDED 31 AIARCH 2025 FIn•nCl rnvl•w Publk B•n•fit 8t•l•m•rt Tho th olcum Canc•r Q UCL ljenofits Iho ty. outcom68 4nd supAval rale•. pthnl• and thfamlllM bath lo• •MI 0bally. . EnG8olng tho ujmfflunlty In fundralslng of c4Mr few1h, onc(¥mlnll Idar publk parUdlIan tn cwltth 814¥AyL In thkn way. tru•ts¢• •rn •8ll•lknd ttwt th• d•l¥w dDtrand publk ben•llL Acknowhdpmont• Wg extend our SInrn Ihonk8 to ou cA)mmltto• dorKX•, •KI wJpsyJtsrn th ho¥0 ntrIbutOd Iholr tlme. oXPert18e, and g•n8ro8ty thr(ghrt Iho yew. C•notttuU•n Th• ¢hitys govwnlng d0mont l• ItsTnJ•t 0•gd dIj 2011 r<•J •mond•d 27 Octob•r2011. The tru•08 a•red duty th• and w) toth• d•1• ollh ftmndal *•tom•nts vMr•: S Baghgrf S Hamtii N Hamltton J Margolin MBE S Sampson FCA the Trust Deed.
CURE CANCER UCL CANCER INSTITUTE TRUSTEE8' REPORT (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2025 Tho Tru8lwo' rolkn wa• ooprovod by the Board ofThi8toM. S Hamllton 27 Auouat 2025
CURE CANCER UCL CANCER INSTITUTE INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES OF CURE CANCER UCL CANCER INSTITUTE I report to tho trustees on my examlnatton of thg fmancial 81at8Fn8nts d Cur• Cancer tharfty) forthe year8nded 31 March 2026. UCL canc Institute (the R68ponslbllltl•g ayrfl bas1• of r•wrt As the tNstees of th8 charity you aro ro¥ponslble for weparakn of tho fjnand818tatements In oo>xdarth with the requlrements of thg ChartitOB Acl 2011 (the 2011 Act). I report In r6BpaL of rny oxamlnakn Lrf th8 charfty8 finan1 8tatem6nts cavrfed out undgr seLlon 145 of th8 2011 ACL In carylng out my ex8mlnatlon I havo follcMd all the aWl¢oble Dlro¢th)n$ glvon by the Charity Commlsthn under 8acalon 145(5Xb) of the 2011 ACL Indondon1 uamln•rf8 Statoment Y¢)w att•ntlon Is drawn to the fact that tho tharlty ha8 prnpar•d Iln8nd81 statemgnts in a¢£ttd8 wllh knx)untlng and Reporting by ChaTiUe5 preparfrvJ thelr aInts In 8coJrdan¢ wth Ihe Flnanaal RepoTling Slandard apkllcable In th& UK and Rspubllc of Irolar (FRS 102> In pr&farenLX to thè Aecounting and Reporting by Chaiities: Statement of Rw)mmended PractlGe IsBued on 1 P4>rll 2005 whid) is referrad to In thg gxtant regulattor but ha8 been l undersland that this h88 boen done In othr for IlnancAal 8tstanents to provtdo a true and fakvlew In acc)xdance with GwwrallyA¢¢oPtod A¢o)unttsw Pract1 effectlve lor rep¢)rfing porlods bfjglnng on or after 1 January 2015. I havo nPleted my examln811on. I confimi that matt6rs have Ixxne b my attontlon In ¢onn¢¢tim wlth tho oxamlnatlon gfvlng mo cau8e to bellove Ihqt In any mat•rfal rospo¢t aOuntIng rK¢rds worn )t kept In respect of the charfty as roqyirod ty ge¢lion 130 ofthe 2011 A¢ x tha finan¢lal 8talomgnts do not accord with those records; t fln8ncLql Statements do not comply with Ihe eppllcabh requlrements concemlng th8 ft>mi ond ¢ontgnt of acuunts Set out In the ChartUè8 {Ace4)unts and Reports) Regulations 2008 other than any requtr8menl that tr actounts glve a Irue aNI lalrvwNwhich18 not a matter con8kl8red as part of an Independent oxamlna I have no corum6 and ha comg atyoss no othar matter8 In cxnnodon th• •x8mlnatlon to *thlch attenlon Should be In thts report in orderto enable a proper under8tandlng of the fin•na81 statgmorts to b8 rea¢1%. Slgned: SaTrJay Kumar Sah ACA FCCA Unrt 101. Flr8t Floor C8rv8nte8 H¢)U8e &9 Headst Road Ham. HA11PD Dated: 27 Auguot 2025
CURE CANCER @ UCL CANCER INSIITUTE STATEMENT OF FINANCIAL ACTIVITIES INCLUDING INCOME AND EXPENDITURE ACCOUNT FOR THE YEAR ENDED 31 MARCH 2025 Unro8trl¢tsd Unrn8trlGtod Re8trl¢tsd fvnd& fundB 2026 2024 DOrljun8 and legade8 Charitable actiwuss Inveslments 8.183 31.540 7,160 17.426 1.244 7,160 18,426 1,244 T¢>lal Incomo 25.830 26,830 CharSt8bl8 8CtlvlUes 1.ofK) Not {wondliurnylncom• lorth• yoarf Not movement In fund• (5S.884) 20.248 Fund balon9 8t 1 Aprfl 2024 88,349 68.101 68.101 Fund balonco8 at 31 March 2025 32.665 88W9 88.349 The Statemert offinandal aclMll88 Ind908 am galM and1088•s recognbod In Iho r. I Incoma and eXpondIre dar from conllnulNJ aclvlues.
CURE CANCER UCL CANCER INSTrruTE BALANCE SHEEr ASAT31 AIARCH 2025 Deblors Cash at bank and In haThl 187 33.478 87,519 89,809 Cr•dllorn: nIS fallh¥ wlthln e year 11 (1.01)0) (1,460) 88.349 Incomo fund• 88,349 88,349 S H8mNton
CURE CANCER UCL CANCER INSTITUTE NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2025 Accountlng pollcl Charfty Inhrmallon Cur• Cancr UCL Can(r In8tllut• Is a Larlty regl8ter•d In Engl•nd. reglstratlon numbor 1141310. Its prlndpal offl¢8 Ss Pltt House, 120 Baker Street, London. W1U 6TU. 1.1 A¢¢ountlng Gonv•ntlon Th8 ftn8ndal 8tatsment8 have bogn prepwed In accordanca tho chorfty8 tgmmlng douJment]. th Ch8rlUes AGI 2011. FRS 102 Tr Flnandal Reporung Stsndard aPICable In th• UK and Rgpubllc ol Iroland. ('FRS 102.1 and the Ch8rltle8 SORP 'Ae¢ountlng and Reporlng by Chorltle8: Statement ol Rowmmgndod pract1 appllcfie to chadl186 ppafig tholr accounts In ac<x)rdane4J vAth tho Fln8ndal Reportlng Slandard appllcable In the UK ond R¢publl¢ ol Ireland IFRS 102r (off•ctfv8 1 Jonuory 2019). Th• ¢hadty18 a Publlc B•nfrflt EnW as deflnod by FRS 102. The ¢haty ha8 tak•n advantagg of ts pth81on• In th• SORP for ¢harM88 not to pr•porn o Statun•nt of Ca8h Flo. Tho ffnandal 8tatemont8 hav• d8part•d from ts CharfU•8 {AoUnts and R•port8) Regulallon8 2008 onty to the extent requlrod to provldo a truo and falr vlow. Th15 dgparturo ha8 Involved followlng the $ts1omonl ol R8mmended Practt¢o for ¢hadlt08 8pptylng FRS 102 rather than th• vernlon ol Iho St•tom•nt of R0mManded Prad¢• whl¢h16 rolerred to In th• Rogulatkns but whlch 8lnce been wlthdrawn. Tho IlDand•l 818tom•nt8 aro pr•pared In 8t8rllng, whlch 1$ the funellon•l ¢Uff•n¢y of the tharfty. Mon•t4ry amount• In th¢80 Itnan¢lal atat•monl8 rounded to the n•4re8t £. Tho finandal 8tat•monts have bo•n pr•p•r•J wd•r thfr hlbtorfcal ca)•t c4)nv•nllon.Tho prfndp•l acctyJnllnq pollcl88 adopted ere 8et out below. IA Qolng oonc•rn At tha tlmo of appm%rfng the flnandal thl•m•nl8, th• Iru•tots ha 8 rnaaonable oxp•cthn that tw h adgqualfj rnsource8 to conllnufj oparafjonal ox1$tsn for the foreseeable futuro. Thu8 ttw conilnue to adopt thg gobng a)nrn basls of a¢counttng In prorIng the ilnanclal 8tatsmants. la Ch•rlt•bl• fvnd• Unr88tddod fund8 4rn 8valhbh lor UB• at ts d•cretlon of lh• trt0•S In fw1horanL* of tholr tharftabl• obloctlv••. Rgfjtrk fund8 wo 8ubJo¢t to 8p•dft¢ ¢ondlttono by doMr8 88 to th•y m•y be 8. Thg purpws and U8e8 of re8trktod fvnd8 aro ¥•t out In the not08 to the flnanclal 8tatemenl8. End¢Jwrnont funds ore 8ublg¢t lo opKlflc (ndlon9 by donorn trtal the capltal mu61 be mah)talned ty th• charfty. 1A Incom• Inm910 rgwgn15ed whgn Ihg dwrfty Is18g8lly enthled to It oftor any perfono corulAbn6 hove been met, tho •mounts ¢on bo measured rellabty, and It i• probAblo tho1 In¢omo wlll be re¢olv¢d. Co8h donatlon8 are rQgnISed on recelpL Other don8Uon8 are recognlsed On tho charfty h#8 b88n notffl8d of the donallon. unle88 perfomwnce conOn9 rnqulre deferral of the amounL Inrne tax recoverable In rel•tlon lo donation6 recelved undar G5ftAld or de8d8 of o)Von•nt Is rery)gnkggd at the dme of the dortakn. Legad88 are r8cognl8od on recglpt OT othenv18e 11 thg charfty haB beon noufted of on Impwdng d&trlbutkM), th8 amount 18 known. and receipt 18 expgdod. If the emounl 18 not known. Ihe 1ogaLy 18 tr8at6d 86 a Itlnggnt a880t.
CURE CANCER UCL CANCER INSTITUTE NOTES TO THE FINANCIAL STATEME (CONTINUED> FOR THE YEAR ENDED 31 MARCH 2025 A¢¢wntlng poll¢l88 (Contln 1.5 Expendr• Ewenditure is reLwnSsed once there Is a logal or 0)nStn¥9 obllgauon to transfor ocoftomlc benefft to thlftl paty,11 Is probable that a transfer of économlc bfft8 wlll be rnqulrod In settlemgn( and the amount of tho obllgath)n ¢an bg m98gured rellably. Exp•)dltur• Is dassffied by acty. The costs ol each acuvlty are made up of tha tot81 of dIrt costs 8nd shared Gosts. indudlng support costs Involved In und¢rtaking each actlvlty. Olrect costs attrfbLrtatAe to a stngle aCtsty 8re allocated threclly to that acllvlty. Sh8r8d rxists whlch conldbute to more than ona acbvlty and support o)sts whlch arg not 8ttrlbulable to a glngla actlvjty are apporlongd belween those actlv1ts8 on a ba818 ¢on$istsnt the use of resources. Contral stsff costs are allocatad on th8 basls of 8pont. and d8pradallon charg88 arg allocated on the poruon of th6 ass•t'$ u88, 1.6 Caih and wh oqulvthnt8 Cash ar¢d cash equivalgrts includo cash In tr&ond. depostt8 hetd at ¢all wlth banks. other Sterrn Ilquld Investments orfglnal matyriYo$ of month8 or le88. and bank ovordrafts. Bank olraft$ are 8hrNm ythin bOrrovngS In current lièbllitl¢s. 1.7 FInan¢1 In•trumgnts The ctarfty h88 818cleO to aPFly tho wovknlorn of Secllon 11 '88sk FlnarKlal Instrum8nt8' and Sectkjn 12 'Olher FlnancAal InStrumts Is¥uo$' Of FRS 102 to all of N8 finandal Inthmgnts. Flnanclal In8tNments ore remgnlsed In the charlV8 balartce sheot whon the tharlty b8come8 paty to the contraclual prO810n8 of th8 k18trument. Flnanclal a88ats and Ilabilittas arg 01tsgL wlth the net amour)ts prnsgnted In tho finandal statements. when thwe Is a legally enforceablé right to $6t off tha rwnlsed amount8 and thor8 on Intentlon to Sewe on a nat ba81s or to roallse thè 88681 and th8 Ilablllty stmultaneously. Baslc fln8nclal a88¢ts. whlch indude debtors and ¢ash and b8nk balances are Initially measured al tran8aclk)n prfc& indudlng Iransaclion ¢08ts and aro sub8equenty cath$d al amofllsed cost uslng the gffgctlve Intsrgst method unl8$9 th8 8ng&m8nt ryJnstltytss a finandng transactlon, where Ihe tran50Ctton 18 measured at the presanl value of thg fulure receipts dlscounted at a matht re of Inter¢st. Flnandal assets cLIlled as recalv8bl• wlthln ono yaar are not amortw. 84slc flnanclalllablUN•s Baslc flnartctal Ilabllllles. Indudlng crodttors end bank loan8 are Inltl8lly recognlged at tr8nsactlon prlco unless the arr8ngem8nt con$litul8s a finan¢ing tran8athon, where tha debt Instrumont 16 me8¥uYed at tho pres8nt value of tha fulure paymants dlscounted at a marf(et rate of Intore8L Flnand81 IlablllUe8 da$8ffied •$ poyablo vAthln one year arn not 8morbsed. Dabt Instruments aro 8ubsequgnUy 1rted at amortlsed c<¥il. ualng the effecuvo Intsr8St rate rne1d. Trade credltors are obllgallons to pay for goods or sery1$ that havo b8en acqulred tn tho ordlnary COU of opor8tlon8 from SUFpllers. thounts payablo ar8 dassffied as ujrrent IFablllUe8 tf paymènt 1$ du? wrthln on• ygar or less. If no( they are presented as nonw¢urront liablllUg8. Trade credIt5 arg recogni88d Inlllally at tran8a¢fjon prf¢e and 8ubsequ9nty me8surod at amortlsod o)st uslng tho effe¢Uv8 Intorest mgthod. D¢rn¢ognltlon of ffn•nclal Ilabllllle8 Financlal Ilabllldes a d$regnISed when the tharws contradual obllgatlorffj explre ¢y are d18thargod or •ncelled.
CURE CANCER @ UCL CANCER INSTITUTE NOTES TO THE FINANCIAL STATEMENT8 {CONTINUED) FOR THE YEAR ENDED 31 MARCH 2025 ¢rttl1 a¢¢ountlng •stlmato0 and Judg•m•nts In the applEcaUon of the charW$ accAiunllng pomdes. the arn rwulrod to mok8 ludgemenis. eBtlmates and a88umptlons about the c4rrylng amount of a850ts and118bllltta$ that ora not readlty apparnnt from oth•r 8¢yJrce& The 08dmate8 and 888oclatsd a88umptson¥ are ba8ad on hl8tortcal oxporfence and other f8ctor8 that are con8ldered to be relovant. Adu81 fe8uIts may dlffer from the8a 08tlmato& Th• e8ttm81•8 and undorfylng a88umptbM are r•v1¢d on an ongolng ba6L8. R&vl8hn8 lo accounllno 98IMat ar6 recognl88d In th8 pwlod In whlch the 08tlmata 18 wh•M th• rnv181on affacts LY¢ly that pedod, or h lh8 parfod of tho revl8lon and future pgrfod8 the rovl8k>n affe¢ts th)th cuTh•nt and fvlure p•rlod8. Oonallon$ l•94cl lund• fund• 2026 2024 Donalton8 and g1ft8 Grants #nd glft ald dm& 3,804 4,579 8,914 8,183 7,180 Charftsbl• a¢tlvlll•• Total tsnd• Tothl lund8 2026 2024 Tl¢ket $81 Othfjr Inr4yn• Evonl In¢om& 18.706 1,721 31,640 31,540 18.426 Analys1• by fund Uftre8trlcted funds 31,640 17.4 1.000
CURE CANCER UCL CANCER INSTITUTE NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2025 Invg•tm•nts Unr•strlcted UnrnBtrlotgd fund• 2025 21)24 Interest receivable 1,244 Charflablo a¢llvllles Support ol UCL C4n¢•r In8lllu Funds 2025 Funds 2024 VeroJ8 Htre Event producuon costg Gon¢ral ¢xpan6e8 Stal£on¢ry Independant examlnalion Donatlon to UGL 4.710 4,635 2,476 147 1,000 85.000 76 95,492 95,492 6.582 Andkn by lund Unrostttted lund8 Re8tr1ctgd funds 95,492 5.582 1,000 During tha finanaal ygar, thg thaiity madg a donauon of£8S.000 to support a re8earch pmlo¢t18d by a d¢xtor afflllaied wllh the UCL CarK•r In$tUla. Thg donayon wa8 8pgclftcally deSnated to advanco on¢6r re86arch in Ilne with tho charit¥ obiectrrfes. Tfuot¢ Durfng Ihe year. no truste95 rocfjlved any remuneratlon or other banefits (2024: £NIL). Ourtng Ihg year ended 31 March 2025. no 8ypon888 havo tjegn InvThd (2024.. £NIL). The average monthly number OfernoYe8S durlng tho year was: 2025 NumlJ•r 2024 -10-
CURE CANCER UCL CANCER INSTITUTE NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2025 efflploy•g8 (ContInd) ¢harlly hao no amploye88 and Sts only Koy managemont por80rn01 are th• tru8te8B {2024. tho sam• Tax•tlon The chadty Is oxempt from tax on Ints)mo and gdni fallkng wlthln CtIOn 505 of tho TsACt 1988 orfj•cllon 202 of th• Taxallonof Chargoablo Galn8 Act 1992 to th• •xMt that th•80 am appllad to It8 charftabl• otyec 10 1)1•1• Amount• IAlllno dufr wlthln on• y•ar. Pr•paymonts and lax reco¥8r#bl8 187 11 Cr•dltorn: amounts falllng duo wlthln ono y••r Accwolj ond def•rr•d tnMm• 1,¢X)O 1.480 12 R•lat•d party tran•a¢tton• Thorn ¥1• no d18d0ble rel•lod wAty tran8a¢llon• durtng tho 8T12024- norn), 11